{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:38:04Z","timestamp":1784806684709,"version":"3.55.0"},"reference-count":9,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Case Rep Dermatol"],"abstract":"<jats:p>Introduction: This case report describes the clinical course and treatment of generalized pustular psoriasis (GPP) flare with intravenous (i.v.) spesolimab, an anti-IL-36R antibody, and subsequent long-term disease management with subcutaneous (s.c.) spesolimab. Case Presentation: A 72-year-old female patient had an ongoing GPP flare for 1 month before presenting to the hospital for flare and related multiorgan failure. She was successfully treated with 2 infusions of 900 mg i.v. spesolimab 1 week apart. She then initiated therapy with 300 mg s.c. spesolimab every 4 weeks for the long-term treatment of GPP. Rapid and significant improvement of skin and systemic symptoms was observed within 1 week of receiving i.v. spesolimab. However, the severity of the patient\u2019s prolonged flare deteriorated her functional status, and she required rehabilitation post-discharge. At follow-ups, s.c. spesolimab demonstrated favorable efficacy and tolerability, with no flare recurrence. Mild superficial desquamation reappeared in the days before consecutive spesolimab doses, with complete skin recovery achieved post-dose. Conclusion: This case underscores the serious complications arising from untreated flare and the need for long-term management of chronic GPP. The patient\u2019s ongoing post-flare symptoms highlight the chronicity of GPP, and continuous targeted treatment with spesolimab improved both her symptoms and quality of life.<\/jats:p>","DOI":"10.1159\/000552213","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:01:05Z","timestamp":1777564865000},"page":"363-371","source":"Crossref","is-referenced-by-count":1,"title":["Management of Generalized Pustular Psoriasis Flare with Intravenous Spesolimab Followed by Long-Term Treatment with Subcutaneous Spesolimab: A Case Report"],"prefix":"10.1159","volume":"18","author":[{"given":"Angad Arinder","family":"Chadha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-022-00881-0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111563"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01378-8"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18851"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00493-0"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.01.089"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/jdpa.0000000000000031"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X241235451"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.25251\/skin.8.supp.370"}],"container-title":["Case Reports in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000552213","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:07:18Z","timestamp":1783008438000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000552213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":9,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000552213","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.32132212","asserted-by":"subject"}]},"ISSN":["1662-6567"],"issn-type":[{"value":"1662-6567","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}